Kyntra Bio (KYNB) vs. Its Competitors Critical Review

Kyntra Bio (NASDAQ:KYNB) is one of 458 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its peers? We will compare Kyntra Bio to related companies based on the strength of its valuation, dividends, analyst recommendations, risk, earnings, institutional ownership and profitability.

Volatility and Risk

Kyntra Bio has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Kyntra Bio’s peers have a beta of 5.46, meaning that their average stock price is 446% more volatile than the S&P 500.

Insider & Institutional Ownership

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 39.3% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Kyntra Bio and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	0	0	1	2.50
Kyntra Bio Competitors	4891	9971	15998	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 141.46%. Given Kyntra Bio’s peers higher probable upside, analysts clearly believe Kyntra Bio has less favorable growth aspects than its peers.

Profitability

This table compares Kyntra Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,598.55%	N/A	-26.27%
Kyntra Bio Competitors	-2,628.08%	-359.45%	-43.11%

Valuation & Earnings

This table compares Kyntra Bio and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyntra Bio	$8.30 million	-$47.58 million	0.14
Kyntra Bio Competitors	$429.29 million	-$67.77 million	-10.93

Kyntra Bio’s peers have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Kyntra Bio beats its peers on 8 of the 13 factors compared.

Kyntra Bio Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.